XML 48 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
 6 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Awards Outstanding
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:
March 31, 2025
2013 Plan2021 PlanInducement AwardsTotal
Granted and outstanding awards:
Options891,211 32,151 602,355 1,525,717 
Restricted stock units1,500,000 3,939,734 494,009 5,933,743 
Total2,391,211 3,971,885 1,096,364 7,459,460 
Schedule of Share-Based Payment Arrangement, Expensed
The following table summarizes stock-based compensation expenses included in operating expenses:
Three Months Ended March 31,Six Months Ended March 31,
2025202420252024
(in thousands)
Research and development$7,264 $7,097 $14,110 $15,413 
General and administrative7,817 9,491 15,147 18,860 
Total$15,081 $16,588 $29,257 $34,273 
Schedule of Summarized Information about Stock Options
The following table presents a summary of the stock option activity for the six months ended March 31, 2025:
SharesWeighted-
Average
Exercise
Price
Per Share		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding at September 30, 2024
1,978,516$23.39 
Granted—— 
Cancelled or expired(30,466)43.12 
Exercised(422,333)7.67 
Outstanding at March 31, 2025
1,525,717$27.35 3.7$3,831,887 
Exercisable at March 31, 2025
1,525,717$27.35 3.7$3,831,887 
Schedule of Share Activity Related to RSUs
The following table summarizes the activity of the Company’s RSUs:
Number of
RSUs		Weighted-
Average
Grant
Date
Fair Value
Per Share
Outstanding at September 30, 2024
4,913,312$49.61 
Granted2,576,81919.88 
Vested(1,337,263)44.15 
Forfeited(219,125)33.97 
Outstanding at March 31, 2025
5,933,743$38.49